GAITHERSBURG, Md., Feb. 6 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that Stanley C. Erck, the company's president and chief executive officer, will present at the 10th Annual BIO CEO & Investor Conference in New York City on Tuesday, Feb. 12. Mr. Erck's presentation will begin at 2 p.m. Eastern Time in the in New Amsterdam Suite of the Waldorf-Astoria.
Mr. Erck will give an update on corporate and clinical milestones and detail the results for the company's successful Phase 2 field trial of a patch-based, needle-free vaccine for travelers' diarrhea.
To access the live audio webcast or the subsequent archived recording, log on to the Investor Relations section on the Overview page of the Iomai website at http://www.iomai.com. Please connect to Iomai's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.
ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.
|SOURCE Iomai Corporation|
Copyright©2008 PR Newswire.
All rights reserved